Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS (“Pharma Nordic”) to extend the territory covered by their exclusive distribution agreement for Bentrio® to Sweden and Denmark. Following the successful launch in Norway earlier this year, Pharma Nordic intends to introduce the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year.
Related Post
- Celldex Therapeutics to Present at Upcoming Investor Conferences - September 13th, 2024
- NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences - September 13th, 2024
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 13th, 2024
- One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations - September 13th, 2024
- Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company - September 13th, 2024
- Generation Bio to Present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs - September 13th, 2024
- Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 - September 13th, 2024
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in... - September 13th, 2024
- Immunocore to present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros - September 13th, 2024
- Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC - September 13th, 2024
- XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - September 13th, 2024
- Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- MBX Biosciences Announces Pricing of Initial Public Offering - September 13th, 2024
- FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy - September 13th, 2024
- Valneva Announces the Success of its Private Placement Raising approximately €60 Million - September 13th, 2024
- Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO - September 13th, 2024
- NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report - August 25th, 2024
- Burning Rock Reports Second Quarter 2024 Financial Results - August 25th, 2024
- Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin... - August 25th, 2024
- Vistin Pharma ASA: Second quarter and first half 2024 financial results - August 25th, 2024
- PCI Biotech: Invitation to first half interim 2024 results presentation - August 25th, 2024
- AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema - August 25th, 2024
- XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders - August 25th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 25th, 2024
- CytoDyn Engages Leading CRO For Phase II Inflammation Trial - August 25th, 2024
- OKYO Pharma CEO Interview to Air on Bloomberg TV - August 25th, 2024
- Wendy Vlieks Appointed as President of The Genome Partnership, Succeeding Leisa Zigman - August 25th, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 25th, 2024
- Thermo Scientific™ VisionMate™ HSX High Speed Barcode Reader Integrates with eLabNext Platform - August 25th, 2024
- Eyenovia Announces Closing of Public Offering - August 25th, 2024
- NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences - August 25th, 2024
- SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome - August 25th, 2024
- ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics - August 25th, 2024
- HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction - August 25th, 2024
- Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - August 25th, 2024
- Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - August 7th, 2024
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 - August 7th, 2024
- Cytek Biosciences Reports Second Quarter 2024 Financial Results - August 7th, 2024
- Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update - August 7th, 2024
- FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update - August 7th, 2024
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results - August 7th, 2024
- Supernus Announces Second Quarter 2024 Financial Results - August 7th, 2024
- Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights - August 7th, 2024
- Certara Reports Second Quarter 2024 Financial Results - August 7th, 2024
- Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 7th, 2024
- Cellectis Provides Financial Results for the Second Quarter 2024 - August 7th, 2024
- UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates - August 7th, 2024
- Travere Therapeutics to Present at Upcoming Investor Conferences - August 7th, 2024
- ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 - August 7th, 2024
- Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib - August 7th, 2024
- BioVie Inc. Announces Reverse Stock Split - August 7th, 2024
- Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 - August 7th, 2024
- Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024 - August 7th, 2024
- Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. - August 7th, 2024
- Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer - August 7th, 2024
- Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - July 13th, 2024
- Virbac: Termination of the liquidity contract - July 13th, 2024
- GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment - July 13th, 2024
- Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory... - July 13th, 2024
- Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 - July 13th, 2024
- Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - July 13th, 2024
- Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback - July 13th, 2024
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants - July 13th, 2024
- Spectral Medical Inc. Announces Change to Auditor - July 13th, 2024
- Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors - July 13th, 2024
- Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024 - July 13th, 2024
- Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - July 13th, 2024
- Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression - July 13th, 2024
- Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS... - July 13th, 2024
- FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone - July 13th, 2024
- Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming... - July 13th, 2024
- Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) - July 13th, 2024
- BioSenic S.A. : Transparency notification received from Véronique Pomi - July 13th, 2024
- Clene to Present at the Emerging Growth Conference - July 13th, 2024
- Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference - July 13th, 2024
- Kraig Biocraft Laboratories Expands Facilities to Support Spider Silk Production Growth - July 2nd, 2024
Tags: